← 29 October 2026's Current Affairs · Science & Tech GA Prelims ★★★★☆ Mains ★★☆☆☆
India rejects patent bid for drug-resistant TB treatment
ಸುದ್ದಿಯಲ್ಲಿ ಏಕೆ?
A new form of an old drug: why Section 3(d) blocks it, the evergreening test for GS3 IPR
India rejects a drug-resistant TB patent bid; Section 3(d) guards against evergreening.
Why it matters: factual, Prelims-type
What you need to know
2 ನಿಮಿಷ
India has rejected a patent bid for a treatment of drug-resistant tuberculosis, and civil society groups have urged the U.S.-based Global Alliance for TB Drug Development to withdraw its application.
Section 3(d) of the Patents Act, 1970 bars patents on new forms of a known substance unless they show significantly enhanced efficacy, a safeguard against evergreening.
ಮೂಲಗಳು: Topper IAS editorial (PIB / The Hindu / Indian Express)
ಮುಖ್ಯ ಅಂಶಗಳು
Remember these
- India rejected a patent application for a treatment of drug-resistant tuberculosis.
- Civil society groups urged the U.S.-based Global Alliance for TB Drug Development to withdraw its application.
- Section 3(d) of the Patents Act, 1970 bars patents on new forms of a known substance unless they show significantly enhanced efficacy.
- Section 3(d) is a safeguard against evergreening, where minor modifications extend patent protection.
- Section 3(d) was inserted by the 2005 amendment to the Patents Act, 1970.
ಪ್ರಿಲಿಮ್ಸ್ · ಮೇನ್ಸ್
How the exam will ask it
ಪ್ರಿಲಿಮ್ಸ್
- Statement: Section 3(d) of the Patents Act, 1970 allows a patent on a new form of a known substance even without any enhanced efficacy. (Incorrect: it bars such patents unless efficacy is significantly enhanced.)
- Statement: Evergreening refers to extending patent protection by minor modifications of an existing drug. (Correct)
- Statement: Section 3(d) is intended to promote access to affordable medicines. (Correct)
ಮೇನ್ಸ್
GS3 (IPR) and GS2 (Health): the issue is evergreening of drug patents, which delays affordable generics for diseases like drug-resistant TB. Section 3(d) of the Patents Act, 1970 permits patents on new forms of a known substance only if they show significantly enhanced efficacy, balancing innovation with public health. The way forward is rigorous examination, pre-grant opposition by civil society, and consistent application of TRIPS flexibilities to keep treatment affordable.
Quick recall
Answer before you reveal
ತಿಳಿದ ವಸ್ತುವಿನ ಹೊಸ ರೂಪಗಳಿಗೆ, ಹೆಚ್ಚಿನ ಪರಿಣಾಮಕಾರಿತ್ವವಿಲ್ಲದೆ, ಪೇಟೆಂಟ್ ನಿರಾಕರಿಸುವ ಪೇಟೆಂಟ್ ಕಾಯ್ದೆ, 1970ರ ಸೆಕ್ಷನ್ 3(ಡಿ)ಯ ಉದ್ದೇಶ ಯಾವುದನ್ನು ತಡೆಯುವುದು?
- ಸಮಾನಾಂತರ ಆಮದು
- ಕಡ್ಡಾಯ ಪರವಾನಗಿ
- ಪೇಟೆಂಟ್ ಪೂಲಿಂಗ್
- ಎವರ್‌ಗ್ರೀನಿಂಗ್ (ಪೇಟೆಂಟ್ ಅವಧಿ ವಿಸ್ತರಣೆ ತಂತ್ರ)
ಉತ್ತರ ನೋಡಿ
ಉತ್ತರ: D — ಸರಿಯಾದ ಉತ್ತರ ಎವರ್‌ಗ್ರೀನಿಂಗ್. ಸಣ್ಣ ಮಾರ್ಪಾಡುಗಳ ಮೂಲಕ ಪೇಟೆಂಟ್ ರಕ್ಷಣೆ ವಿಸ್ತರಿಸುವುದನ್ನು ಸೆಕ್ಷನ್ 3(ಡಿ) ತಡೆಯುತ್ತದೆ.
Convert this topic into marks
Today's 10-MCQ test · instant analysis · Powered by AdaptIQ